Search

everythinglearnresearchcommunity

for

Search:↓

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Low dose methotrexate does not increase hair fall and may reduce it.

Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Tofacitinib may help treat severe hair loss, but more research is needed.

Treatment with plasma rich in growth factors improved hair density and thickness for hair loss patients.

Certain immune system proteins are important for skin healing but can cause problems if there are too many of them.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

The conclusion is that acne, alopecia, and hyperhidrosis are common skin issues with various treatments available, and accurate diagnosis is key for effective management.

Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.

Regenerative pharmacology, which combines drugs with regenerative medicine, shows promise for repairing damaged body parts and needs more interdisciplinary research.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Monochromatic light devices, especially the 308-nm excimer laser, are promising for treating alopecia areata but more research is needed.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.

Understanding how epigenetic regulation affects stem cells is key to cancer insights and new treatments.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.

Mice without the IL-6 gene had more hair growth after injury due to higher activity of a related protein, Stat3.

Dengue virus can infect human hair follicle cells and may cause hair loss.

The workshop discussed the role of a protein called calreticulin in health and disease, its potential as a treatment target, and its possible use as a disease marker.

Higher Lnk protein levels in ovaries may lead to insulin resistance in women with PCOS.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Hair growth environment recreated with challenges; stem cells make successful skin organoids.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Adolescents with severe alopecia incur significantly higher healthcare costs.